-
Hainan Haiyao Concludes Phase I Clinical Study for PaiEnJiaBin, a Novel KCNQ Agonist
•
China-based Hainan Haiyao Co., Ltd (SHE: 000566) has announced the conclusion of Phase I clinical studies for PaiEnJiaBin, a Category 1 chemical drug co-developed with the Shanghai Institute of Materia Medica. PaiEnJiaBin is a next-generation KCNQ potassium channel agonist, with no similar products approved globally, and is being developed to…
-
Sino Medical Sciences Technology to Acquire Majority Stake in US Endovascular Device Firm eLum
•
China-based Sino Medical Sciences Technology Inc., (SHA: 688108) has announced plans to acquire a 72.73% stake in eLum Technologies Inc., an early-stage endovascular medical device company based in California, US, for USD 20.73 million. Upon completion of the deal, eLum will become the controlling subsidiary of Sino Medical Sciences Technology.…
-
Acotec Scientific Holdings Receives Marketing Approvals for Vericor-14 Microcatheter in Japan and Thailand
•
China-based Acotec Scientific Holdings Ltd (HKG: 6669) has announced that it has received marketing approvals from the Ministry of Health, Labour and Welfare of Japan and the Thailand Food and Drug Administration for its Vericor-14 microcatheter. This regulatory clearance marks a significant milestone for the company’s product, which can now…
-
MSD’s Gardasil 9 HPV Vaccine Demonstrates 10-Year Efficacy in Adolescents
•
Merck, Sharp & Dohme (MSD; NYSE: MRK) has released long-term effectiveness data for its recombinant human papillomavirus (HPV) 9-valent vaccine, Gardasil 9, in minors aged between 9 and 15 years old. The results indicate that the immunogenicity generated by the vaccine persisted for 10 years after the third and final…
-
Sinovac Biotech Directors Reject Alternative Liquidity’s Lowball Tender Offer
•
China-based Sinovac Biotech Ltd. (NASDAQ: SVA) announced that its Board of Directors has unanimously determined that the partial tender offer by Alternative Liquidity Index LP to acquire up to 10,000,000 common shares of Sinovac for USD 0.03 apiece in cash is not advisable and is not in the best interests…
-
Abbott to Acquire Insulin Management Firm Bigfoot Biomedical
•
Healthcare giant Abbott (NYSE: ABT) has announced an agreement to purchase Bigfoot Biomedical, a company specializing in insulin management systems. The transaction is expected to be completed this month, subject to the fulfillment of customary conditions. Financial details of the acquisition were not disclosed. History of Collaboration and Continued PartnershipAbbott…
-
Taizhou Port Designated as Drug Import Port by NMPA and General Administration of Customs
•
The National Medical Products Administration (NMPA) and the General Administration of Customs have released a joint notification designating Taizhou Port in the city of Taizhou as a drug import port. This designation allows for the importation of certain Chinese medicines and chemicals, including narcotics and psychotropic drugs, through Taizhou. Enhanced…
